Sir,
We would like to make comment on the above article, which as its main conclusion found that abnormal p53 was associated with failure of response to radiotherapy in patients with rectal cancer. Our department has recently conducted a similar analysis focusing purely on rectal cancer undergoing neoadjuvant treatment and the conclusions that we drew were somewhat different.
In total, we sourced 22 studies that assessed p53 status in this setting. Of these, 18 used immunohistochemistry (IHC) and only four (18%) showed that it could predict response. A further six studies assessed the p53 gene directly, four using single-strand conformational polymorphism analysis (ssCP) (Sakakura et al, 1998; Elsaleh et al, 2000; Rau et al, 2003; Saw et al, 2003) and two using direct p53 gene sequencing (DGS) (Kandioler et al, 2002; Rebischung et al, 2002). No study (0%) where ssCP was used could predict response. While both the studies where DGS was used showed that tumours manifesting mutations in p53 were less likely to respond, we feel that these results should be interpreted with caution for several reasons.
Firstly, patients in both DGS studies underwent short-course radiotherapy, whereas there is an increasing use of long-course neoadjuvant radiochemotherapy (RCT) as standard of care in many institutions (Sauer et al, 2004). Also, the pathological end point used in both studies was a decrease in T stage determined by comparison of pretreatment transrectal ultrasound (TRUS) and postoperative pathological staging, which may be unreliable. For example, a recently published study of 1184 patients undergoing pretreatment staging by TRUS found that it had an overall staging accuracy of 69% due to its limited depth of acoustic penetration preventing accurate staging of locally advanced tumours (Garcia-Aguilar et al, 2002). In addition, specific analyses of tumours that have undergone a decrease in T stage post-RCT showed that up to 41% of these may harbour residual tumour deposits in the lymph nodes (Medich et al, 2001; Zmora et al, 2004).
We therefore feel that the conclusion of this study, based principally on the results of two papers, is a little premature. What does seem apparent, however, is that IHC and ssCP analysis of p53 yield unreliable and heterogeneous results. While DGS may hold promise, the question of whether such an expensive and labour-intensive technique will become useful in the clinical setting still remains to be answered.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B (2000) Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56: 239
Garcia-Aguilar J, Pollack J, Lee SH, Hernandez de Anda E, Mellgren A, Wong WD, Finne CO, Rothenberger DA, Madoff RD (2002) Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 45: 10
Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kuhrer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Potter R, Jakesz R, Teleky B, Herbst F (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235: 493
Medich D, McGinty J, Parda D, Karlovits S, Davis C, Caushaj P, Lembersky B (2001) Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathological findings and clinical implications. Dis Colon rectum 44: 1123
Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dorken B, Daniel PT (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21: 3391
Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100: 131
Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, Kimura A, Taniguchi H, Hagiwara A, Yamaguchi T, Inazawa J, Abe T, Takahashi T, Otsuji E (1998) Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. Br J Cancer 77: 159
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731
Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ (2003) p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46: 192
Zmora O, Dasilva GM, Gurland B, Pfeffer R, Koller M, Nogueras JJ, Wexner SD (2004) Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum 47: 1607
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Smith, F., Stephens, R., Kennedy, M. et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92, 1813 (2005). https://doi.org/10.1038/sj.bjc.6602589
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6602589
This article is cited by
-
Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer
Cell & Bioscience (2015)
-
Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer
International Journal of Colorectal Disease (2009)